Analysis of hemodialysed patients immune response to anti - Hepatitis B vaccination performing dialysis with an high capacity adsorbent polymethylmethacrylate membrane

Not Applicable

• Conditions: End Stage Renal Disease patients immune system response to Hepatitis B vaccination; Inflammatory and Immune System - Other inflammatory or immune system disorders; Renal and Urogenital - Kidney disease

• Registration Number: ACTRN12611000809932
• Lead Sponsor: SL 8 Arezzo P.O. Ospedale S. Donato di Arezzo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-08-02
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

End Stage Renal desease patients on mainteinance thrice-weekly dialysis treatment who had been defined as non-responder to Hepatitis B vaccination according to CDC criteria

Exclusion Criteria

End Stage Renal desease patients on mainteinance thrice-weekly dialysis treatment who had been defined as non responder to Hepatitis B vaccination according to CDC criteria already using any kind of polymethylmethacrylate membrane dialyzers at the initial time of observation

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Efficacy of anti-Hepatitis B vaccination in patients treated with polymethylmethacrylates membrane dialyzers. We expect a difference in the two groups of more than 25% in the number of patients with positive antibody response (Ab HBs > 10%) after the last dose of vaccine (booster).[Four months after starting observation period]

Secondary Outcome Measures

Name	Time	Method
Polymethylmethacrylate dialyzers are able decrease pre-dialysis serum level of sCD40 (soluble form of CD40)[Three months after starting observation period]